SHOULD WE MEDICATE A CHILD WHO HAS ADHD?

The choice is neither a test of good parenting nor a vote on medication. It’s a clinical decision that needs evidence, consent and follow-through.

Few decisions provoke more parental unease than whether to give a child medication for ADHD. One parent fears changing their child’s personality; another fears withholding something that might make school, friendships and daily life less exhausting. Both concerns deserve to be taken seriously. The wrong question is whether medication is good or bad in principle - the useful one is what this particular child needs, and how we’ll judge whether treatment is helping.

The evidence supports real potential benefit, but not a universal response. A 2023 Cochrane review — a systematic assessment of published research by an independent international network — examined 212 randomised trials involving 16,302 children and adolescents. Researchers compared methylphenidate with a placebo or no treatment and found that it may improve ADHD symptoms and general behaviour, particularly when assessed by teachers. But most trials were short, often around a month, and the review rated the certainty of its findings as very low, (partly because side effects could reveal who was taking the medicine). A more robust 2025 review in The BMJ found evidence of short-term symptom improvement with ADHD medicines. So the overall message is not that medication is unproven, but that benefits must be assessed individually and long-term outcomes remain less certain.

In England, NICE recommends considering medication from the age of five when ADHD continues to cause significant impairment despite appropriate adjustments at home or school. For children under five, an ADHD-focused parent-training programme is the first-line approach and medication requires exceptional specialist consideration.

What counts as success following medication? A child may find it easier to follow a conversation, complete work without constant correction, regulate frustration or sustain friendships. Others may find the improvement modest, or feel that a side effect outweighs the gain. Better classroom compliance, by itself, isn’t a sufficient outcome, the child’s own account of what feels easier — and what doesn’t — should sit alongside feedback from parents and teachers.

Side effects also deserve plain language. With methylphenidate, the more common non-serious effects include reduced appetite, difficulty sleeping, headaches, stomach aches, nausea and sometimes weight loss. Some children experience irritability or emotional changes and these should be discussed promptly, especially if pronounced. Stimulants can also raise pulse and blood pressure slightly, and treatment may affect growth over time. Tics, significant mood changes, palpitations or other concerning symptoms need individual medical review. ‘Non-serious’ in a research paper does not mean irrelevant to a child’s everyday life.

Monitoring is therefore part of treatment, not an administrative afterthought. Before prescribing, clinicians should assess physical and mental health, current medicines, relevant family and cardiac history, height, weight, pulse and blood pressure. NICE recommends blood pressure and pulse checks after each dose change and every six months; height every six months; and weight every three months for children aged ten and under. For older children and young people, weight should be checked three and six months after starting, and at least six-monthly thereafter. Growth should be plotted on an appropriate chart, while appetite, sleep, mood and the child’s functioning should be reviewed throughout. An ECG is not routinely needed unless specific cardiac risks are identified. A specialist medication review should take place at least once a year.

Medication, however, isn’t the only meaningful intervention. ADHD-focused support for parents can help families understand impulsivity, emotional regulation and patterns of conflict without interpreting every difficulty as deliberate misbehaviour. Schools can reduce unnecessary distractions, break tasks into manageable stages, provide written instructions and movement breaks, and offer more predictable routines. Psychological approaches may help children develop planning, problem-solving and emotional skills, and address associated anxiety or low self-esteem. For some young people who continue to experience impairment despite benefiting from medication, NICE advises considering ADHD-focused cognitive behavioural therapy. The goal isn’t to train a child out of their neurodevelopmental differences, but to make daily life more manageable.

Nor does starting medication necessarily mean taking it every day of every year. For some children using stimulant medicines, a specialist may agree a school-day schedule, weekend breaks or a planned pause during holidays — sometimes to reassess need, sometimes because appetite, sleep or growth have become concerns. NICE specifically recommends considering a school-holiday break if growth is significantly affected. But ADHD doesn’t disappear when the school bell rings: difficulties with friendships, emotional regulation and family life can matter just as much outside the classroom. The decision should therefore be based on the child’s functioning across the whole week, not simply on academic demands. Non-stimulants such as Atomoxetine and Guanfacine generally need regular daily dosing; Guanfacine, in particular, mustnt be stopped abruptly - any break or restart should be agreed with the prescriber.

And is ADHD for life? It’s a neurodevelopmental condition, but that doesn’t mean a child’s symptoms, abilities or treatment needs remain fixed. As some young people mature, they acquire strategies, enter environments better suited to them and find that their symptoms cause far less impairment. Some no longer meet full diagnostic criteria; others still have ADHD traits but no longer need medication.

Longitudinal research suggests that the course is often fluctuating rather than a simple story of growing out of it: in one major study, almost two-thirds moved between periods of more and less pronounced symptoms, while sustained remission was less common. Managing ADHD successfully isn’t necessarily the same as the underlying vulnerability disappearing, but it can change what support is needed.

The most productive position is neither automatic enthusiasm nor resistance - it’s a carefully evaluated treatment plan, with a child’s voice at its centre and permission to reconsider as their life changes. The aim isn’t to commit a child to medication for life, it’s to give them the best chance of living well now, and to keep asking whether the treatment still earns its place.

Previous
Previous

WHO’S REALLY STRUGGLING AT WORK?

Next
Next

WHEN THE HOUSE GOES QUIET